Study to Evaluate Vibegron on Patient Treatment Satisfaction Quality of Life and Healthcare Resource Utilization in Patients with Overactive Bladder

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Overactive Bladder
  • Age: Between 18 years - 100 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    Patients must meet all of the inclusion criteria and none of the exclusion criteria at Baseline to be eligible for enrollment in this study:
    1. Male or female, 18 years of age or older at the Baseline Visit.
    2. Able to provide informed consent.
    3. Diagnosis of OAB with or without urgency urinary incontinence by treating healthcare provider or previous healthcare provider.
    4. Symptoms of OAB for at least 3 months prior to Baseline Visit.
    5. Initiating a new course of treatment with vibegron as deemed appropriate per the investigator.
    6. Willing and able to complete electronic patient-reported outcome (PRO) questionnaires monthly for a minimum of one year.
    7. Previous exposure to anticholinergics or mirabegron (Myrbetriq®) monotherapy and/or mirabegron plus solifenacin combination therapy prior to initiation of vibegron.
    8. Has prescription drug coverage under a commercial or governmental insurance plan.

You may not be eligible for this study if the following are true:

  • Patients who meet any of the following exclusion criteria will not be enrolled in this study:
    1. Any contraindication to the use of vibegron per US label.
    2. History of OAB treatment with botulinum toxin A; sacral neuromodulation; percutaneous tibial nerve stimulation; external beam radiation therapy; urinary stents within the last 6 months; pelvic or lower urinary tract surgery within the last 6 months; and urethral catheterizations within the last 3 months prior to Baseline Visit.
    3. History of mixed incontinence where stress incontinence is the predominant form (as determined by the investigator).
    4. Patients at risk of urinary retention (as determined by the investigator).
    5. Neurologic conditions associated with OAB symptoms, such as multiple sclerosis.
    6. Pregnant or breastfeeding or plans to do so during the study.
    7. Participating in another clinical trial with investigational product or device.
    8. Use of vibegron prior to the Baseline visit either prescribed or in a previous vibegron clinical trial where patient was on vibegron.
    9. Anyone who, at the discretion of the investigator, is not suitable for treatment with a beta 3 agonist for OAB for any reason.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.